Katherine Stueland is Chief Executive Officer of GeneDx Holdings Corp. (WGS). The company reported total compensation of $13,547,219 for fiscal year 2025.
| Salary | $715,869 |
|---|---|
| Bonus | $0 |
| Stock awards | $11,738,600 |
| Option awards | $0 |
| Non-equity incentive plan | $1,075,500 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $17,250 |
| Total | $13,547,219 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure GeneDx Holdings Corp. filed April 30, 2026, accession 0001818331-26-000030.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | Chief Executive Officer | $715,869 | $0 | $11,738,600 | $0 | $1,075,500 | $0 | $17,250 | $13,547,219 |
| FY2024 | Chief Executive Officer | $675,000 | $950,000 | $2,796,800 | $0 | $0 | $0 | $0 | $4,421,800 |
Totals as disclosed in each year's own compensation disclosure for GeneDx Holdings Corp..
| Peer-group chief executive median | $8,122,690 |
|---|---|
| Difference from that median | $5,424,530 |
| Percentile within the disclosed peer group | 90th |
| Peers with a disclosed figure | 10 |
Medians and percentiles are computed across the peer group GeneDx Holdings Corp. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Katherine Stueland this page | Chief Executive Officer | $13,547,219 |
| Kevin Feeley | Chief Financial Officer | $4,688,926 |
| Bryan Dechairo | Chief Operating Officer | $3,582,375 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full GeneDx Holdings Corp. compensation brief.
Katherine Stueland's compensation sits inside GeneDx Holdings Corp.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.